Journal of labelled compounds & radiopharmaceuticalsDeuteriumErb-b2 Receptor Tyrosine KinasesCarbon RadioisotopesIsotope LabelingProtein Kinase Inhibitors
Synthesis of BI 1584142 and BI 1810631 (Zongertinib), Two Potent HER2 Inhibitors, Labeled With Carbon-14 and With Deuterium.
Bachir Latli, Eugene Chong
Published: 202510.1002/jlcr.4168
Abstract
BI 1584142 (1) and BI 1810631 (2, zongertinib) are potent and selective HER2 tyrosine kinase inhibitors being developed for the treatment of non-small cell lung cancer. Carbon-14-labeled versions of these drug candidates were needed to study their ab…
Preview only. Read the full abstract at the source